Glen Harbor Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Glen Harbor Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-21,862	Closed	-$501K	–	1312
2018 Q1	$501K	Buy	+21,862	New	+$486K	0.01%	639

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Glen Harbor Capital Management's CNCE Position: Q2 2018 in Review

Glen Harbor Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2018, closing a stake of 21,862 shares — an estimated $501K sold.

Glen Harbor Capital Management first reported a position in CNCE in Q1 2018 and held it in 1 quarter. The position peaked at $501K in Q1 2018. 120 funds tracked by Wall St. Rank hold CNCE as of Q2 2018.

Glen Harbor Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Glen Harbor Capital Management sold 21,862 Concert Pharmaceuticals, Inc. shares in Q2 2018, an estimated $501K.
Glen Harbor Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
Glen Harbor Capital Management's Concert Pharmaceuticals, Inc. position peaked at $501K in Q1 2018.
120 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2018.

Based on Glen Harbor Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.